Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

47.34 +0.48 (+1.02%)
Official Closing Price Updated: 4:10 PM EDT, Jul 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9
...
58 59 Next >
Is Pfizer Stock a Buy?
Via The Motley Fool
Topics Intellectual Property
Laser-Focus on These Tariff-Proof Stocks Before It’s Too Late
Stay calm amid tariff uncertainty with low-valued pharma and European stocks. Discover why these sectors offer protection and potential gains. 
Via InvestorPlace
Topics Government Intellectual Property World Trade
Is Bristol Myers Squibb's High-Yielding Dividend Safe?
Via The Motley Fool
Topics Intellectual Property
Exploring the top movers within the S&P500 index during today's session.
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Tuesday. 
Via Chartmill
Is Bristol-Myers Squibb Gaining or Losing Market Support?
Via Benzinga
Beat the S&P 500 With This Cash-Gushing Dividend Stock
Via The Motley Fool
Topics Intellectual Property Stocks
BMY: A High-Yielding Drug Stock With Great Growth Potential
Bristol-Myers Squibb Co. traces its corporate beginnings back to 1887. Today, the company is a leader in developing innovative drugs like Eliquis for stroke prevention and Opdivo for cancer... 
Via Talk Markets
Topics Stocks / Equities
Exploring the top movers within the S&P500 index during today's session.
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Monday. 
Via Chartmill
5 Ways to Prepare for AI’s ‘Tower of Terror’ Moment
As volatility rattles tech giants, investors are rotating into value stocks for stability and upside. Discover why this five-letter word could be the key to winning in 2025. 
Via InvestorPlace
Topics Artificial Intelligence Economy Government
50-Year-Old Early Retiree Making $175,000 in Dividends Shares Portfolio - 'Now I Spend on Travel, Cars and Doing What I Want'
Via Benzinga
The 5-Letter Word Every Investor Should Memorize to Win in 2025
As volatility rattles tech giants, investors are rotating into value stocks for stability and upside. Discover why this five-letter word could be the key to winning in 2025. 
Via InvestorPlace
Topics Economy World Trade
3 Deeply Discounted Dividend Stocks to Buy Today
Via The Motley Fool
Unpacking Q4 Earnings: Pfizer (NYSE:PFE) In The Context Of Other Branded Pharmaceuticals Stocks
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Pfizer (NYSE:PFE) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
FDA Approves Exelixis' Lead Cancer Drug Cabometyx For Expanded Use In Neuroendocrine Tumors
Exelixis' Cabometyx gains FDA approval for advanced neuroendocrine tumors, while phase 3 data confirms sustained survival benefits in renal cancer. 
Via Benzinga
1 Large-Cap Stock on Our Watchlist and 2 to Brush Off
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth... 
Via StockStory
Topics Retirement
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
BRISTOL-MYERS SQUIBB CO (NYSE:BMY): good value for what you're paying.
BRISTOL-MYERS SQUIBB CO may be an undervalued stock option. NYSE:BMY retains a strong financial foundation and an attractive price tag. 
Via Chartmill
The Stock Market Hates Uncertainty & Loves To Climb A Wall-Of-Worry
In this video lesson, I review the overall market and a new swing position for Monday's session. 
Via Talk Markets
Topics ETFs Stocks / Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness. 
Via Benzinga
2 High-Yield Dividend Stocks That Are Bargain Buys Right Now
Via The Motley Fool
Is BRISTOL-MYERS SQUIBB CO (NYSE:BMY) suited for dividend investing?
Why BRISTOL-MYERS SQUIBB CO (NYSE:BMY) is a Top Pick for Dividend Investors. 
Via Chartmill
Friday's session: top gainers and losers in the S&P500 index
Curious about the S&P500 stocks that are in motion on Friday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
Europe Approves Bristol Myers' Cell Therapy Breyanzi For Patients With Certain Type Of Blood Cancer
EC approves BMY's Breyanzi for relapsed or refractory FL, based on Phase 2 study showing high response rates & sustained efficacy. 
Via Benzinga
These S&P500 stocks are gapping in today's session
Looking for opportunities in today's market? Check out the S&P500 gap up and gap down stocks on Friday and stay ahead of the market trends. 
Via Chartmill
Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst
H.C. Wainwright & Co. initiates a Buy rating on Perspective Therapeutics, citing promising cancer radiotherapy assets. 
Via Benzinga
Bristol-Myers Squibb Co Chart Analysis
Technical analysis of the stock chart for BMY. 
Via Talk Markets
Topics Stocks / Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Bristol Myers Squibb Scoops Up Its Blood Cancer Drug Partner 2seventy Bio In $286 Million Deal
Bristol Myers Squibb to acquire 2seventy Bio for $5.00 per share in a $286 million all-cash deal, an 88% premium to its last close. Expected to close in Q2 2025. 
Via Benzinga
US Stocks Likely To Open Higher After Monday's Selloff: TSLA Stock Rebounds From Its Worst Fall In 5 Years After Trump Backs Musk, Analyst Says 'Pullbacks Are Normal'
U.S. stock futures rose on Tuesday following Monday's heavy selloff. Futures of all four benchmark indices surged in premarket trading. 
Via Benzinga
Topics Government
< Previous 1 2 3 4 5 6 7 8 9
...
58 59 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.